Table 2.
Treatment-Related Outcomes.
| Variable | RFA Group (n = 39) | SBRT Group (n = 33) | P Value | |
|---|---|---|---|---|
| Post-treatment hospitalization, days | 3.00 (2.50–4.50) | - | - | |
| Short-term treatment-related toxicities #, n | ||||
| Pain | 7 | 3 | 0.459 | |
| Fever | 9 | 4 | 0.370 | |
| Gastrointestinal disorders | 2 | 7 | 0.089 | |
| Hematological toxicity | 0 | 2 | 0.401 | |
| Liver toxicities | 0 | 2 | 0.401 | |
| Skin toxicities | 0 | 1 | 0.933 | |
| Response according to mRECIST *, n | 1.000 | |||
| Complete response | 38 | 33 | ||
| Incomplete response | 1 | 0 | ||
| Disease progression, n | 28 | 12 | 0.005 | |
| Local disease progression, n | 23 | 6 | 0.002 | |
NOTE. Data presented as mean (interquartile range), unless otherwise noted. # No greater than grade 3 toxicities effects were observed in both groups. * Tumour necrosis measurements are from 30 days post-TACE. * Tumour necrosis measurements are from 30 days post-TACE.